Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.

doi:10.1038/s41467-024-55378-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.

Nature communications - 2 Jan 2025

Alsaed Bassel, Lin Linh, Son Jieun, Li Jiaqi, Smolander Johannes, Lopez Timothy, Eser Pinar Ö, Ogino Atsuko, Ambrogio Chiara, Eum Yoonji, Thai Tran, Wang Haiyun, Sutinen Eva, Mutanen Hilma, Duàn Hanna, Bobik Nina, Borenius Kristian, Feng William W, Nabet Behnam, Mustjoki Satu, Laaksonen Sanna, Eschle Benjamin K, Poitras Michael J, Barbie David, Ilonen Ilkka, Gokhale Prafulla, Jänne Pasi A, Haikala Heidi M

Abstract excerpt

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are commonly used to treat non-small cell lung cancers with EGFR mutations, but drug resistance often emerges. Intratumor heterogeneity is a known cause of targeted therapy resistance and is considered a major factor in treatment failure. This study identifies clones of EGFR-mutant non-small cell lung tumors expressing low levels of both wild-type...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-Associated Fibroblasts

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Resistance, Neoplasm

Share to Epithelial-Mesenchymal Transition

Share to ErbB Receptors

Share to Protein Kinase Inhibitors

Share to Transforming Growth Factor beta

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 39747003
DOI: 10.1038/s41467-024-55378-5
PMCID: PMC11695629

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.PMID 39747003Read ↗

Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung CancerSemantic proximity Read ↗

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC.Semantic proximity Read ↗

Immunotherapy in EGFR-TKI-resistant NSCLC: Mechanisms, therapeutic strategies, and emerging challenges.Semantic proximity Read ↗

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapySemantic proximity Read ↗

Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.Semantic proximity Read ↗

EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.Semantic proximity Read ↗

Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for ImmunotherapySemantic proximity Read ↗

Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.Semantic proximity Read ↗

Spatial dynamics of the tumor microenvironment linked to emerging resistance in <i>EGFR</i> -mutated lung cancerSemantic proximity Read ↗

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint InhibitorsSemantic proximity Read ↗

The histone-modified landscape: Core mechanisms of osimertinib resistance in EGFR-mutant lung cancer.Semantic proximity Read ↗

Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.